Nevro

Nevro Corp is a publicly traded neurotechnology company headquartered in Redwood City, California, specializing in spinal cord stimulation (SCS) therapy for the treatment of chronic pain. The company is best known for its HF10 platform, a high-frequency SCS system that delivers stimulation at 10 kHz, distinguishing it from conventional low-frequency alternatives. Unlike traditional SCS devices, HF10 therapy is designed to provide effective pain relief without the paresthesia, or tingling sensations, that patients typically experience with older stimulation paradigms. The system has received FDA approval for the treatment of chronic intractable back and leg pain, and is implanted as a minimally invasive device that modulates pain signals along the spinal cord.

Nevro trades on the New York Stock Exchange under the ticker NVRO and has established itself as a significant commercial player in the neuromodulation market since its IPO in 2014. The company has built a compelling clinical evidence base for HF10, including pivotal trial data demonstrating superior outcomes compared to conventional SCS in head-to-head studies. These results have supported broad reimbursement coverage and helped drive adoption among pain management specialists and spine surgeons across the United States and internationally. Nevro has continued to expand its product portfolio and explore additional indications, including the treatment of painful diabetic neuropathy, to broaden its addressable patient population.

Nevro represents an important example of how targeted innovation in stimulation parameters can meaningfully differentiate a medical device within a competitive and established therapeutic category. By challenging the longstanding assumption that paresthesia was a necessary component of SCS therapy, the company helped shift clinical expectations and patient standards across the broader neuromodulation field. Its commercial success has attracted attention to the potential of high-frequency and paresthesia-free approaches, influencing research and development strategies among competitors. For the neurotech industry, Nevro serves as a case study in the value of rigorous clinical evidence and differentiated technology in driving market adoption and reshaping standards of care.